Breaking News
Get 55% Off 0
🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?
Explore for Free
Close

Manulife Dividend Income Balanced Fund A (162212)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.942 -0.036    -3.68%
22/11 - Closed. Currency in CNY
  • Morningstar Rating:
  • Total Assets: 62.67M
Type:  Fund
Market:  China
Issuer:  泰達宏利基金管理有限公司
Asset Class:  Equity
MANULIFE TEDA Dividend Pioneer Stock Fund 0.942 -0.036 -3.68%

162212 Holdings

 
Comprehensive information about top holdings and Key Holding Information for the MANULIFE TEDA Dividend Pioneer Stock Fund (162212) fund. Our MANULIFE TEDA Dividend Pioneer Stock Fund portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 7.130 7.130 0.000
Stocks 92.630 92.630 0.000
Other 0.230 0.230 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 23.373 17.577
Price to Book 2.939 2.212
Price to Sales 4.636 1.726
Price to Cash Flow 19.016 9.656
Dividend Yield 1.463 2.492
5 Years Earnings Growth 20.975 16.876

Sector Allocation

Name  Net % Category Average
Healthcare 89.760 9.773
Consumer Cyclical 4.440 11.033
Industrials 2.880 24.258
Technology 1.800 24.851
Consumer Defensive 1.120 10.946

Region Allocation

  • Asia
  • Emerging Markets

Top Holdings

Number of long holdings: 38

Number of short holdings: 1

Name ISIN Weight % Last Change %
  Hunan Jiudian Pharma CNE1000034Z6 6.28 23.19 -6.38%
  Zhejiang Jolly Pharma CNE100001096 6.04 16.59 -4.76%
  Xiamen Amoytop Biotech Co CNE100003RT3 5.84 71.69 -2.85%
  Shanghai Aohua Photoelectricity Endoscope CNE100004ZJ5 5.30 49.50 -3.90%
  New Industries CNE100003T39 4.82 61.88 -2.35%
  Eyebright Medical Technology Beijing CNE1000041J5 4.71 87.24 -5.25%
  Raas Blood A CNE100000C31 4.56 7.45 -3.37%
  Mehow Innovative CNE100005WP6 4.25 29.10 -2.22%
  APT Medical CNE100004C45 4.25 349.23 -4.33%
  Sinopep Allsino Bio Pharmaceutical Co CNE1000051X5 4.09 52.10 -4.87%

Top Equity Funds by MANULIFE Fund Mgmt Co.,Ltd

  Name Rating Total Assets YTD% 3Y% 10Y%
  Manulife TEDA Trsfmtn Opportunity E 4.31B 40.01 -13.85 -
  MANULIFE TEDA Market Value Selectio 1.52B 19.63 -2.88 5.48
  TEDA Value Optimization Growth Ind 1.35B 44.21 -11.19 7.90
  MANULIFE TEDA RuiZhi WJ Alloc 1.29B 1.57 -1.35 -
  MANULIFE TEDA Industry Selected 675.49M 0.49 -7.14 8.20
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

162212 Comments

Write your thoughts about Manulife Dividend Income Balanced Fund A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email